T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy
- PMID: 12070023
- DOI: 10.1182/blood.v100.1.167
T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy
Abstract
Chronic lymphocytic leukemia (CLL) cells are ineffective antigen-presenting cells (APCs) although CD40-activated CLL cells can stimulate proliferation of autologous and allogeneic T cells. We examined the antigen-presenting capacity of CD40-activated CLL cells as well as dendritic cells pulsed with apoptotic bodies of CLL cells to generate autologous and allogeneic immune responses against CLL cells. Both APC types were capable of generating T-cell lines that proliferate specifically in response to unstimulated CLL cells. Whereas cytotoxic responses against stimulated and unstimulated CLL cells could be repeatedly generated by allogeneic healthy donors, autologous cytotoxic immune responses against CD40-activated and native CLL cells were rarely detected. However, T cells isolated from patients with CLL could recognize and lyse allogeneic stimulated and unstimulated CLL cells, demonstrating that cytotoxic T cells from these tumor-bearing patients are functionally intact.
Similar articles
-
CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.Blood. 1999 Mar 15;93(6):1992-2002. Blood. 1999. PMID: 10068672
-
B-cell chronic lymphocytic leukemia-derived dendritic cells stimulate allogeneic T-cell response and express chemokines involved in T-cell migration.Neoplasma. 2007;54(6):527-35. Neoplasma. 2007. PMID: 17949237
-
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.J Clin Invest. 2008 Jul;118(7):2427-37. doi: 10.1172/JCI35017. J Clin Invest. 2008. PMID: 18551193 Free PMC article.
-
CD40 activation: potential for specific immunotherapy in B-CLL.Ann Oncol. 2004 Jun;15(6):853-7. doi: 10.1093/annonc/mdh213. Ann Oncol. 2004. PMID: 15151939 Review.
-
Vaccine- and immune-based therapy in chronic lymphocytic leukemia.Semin Oncol. 2006 Apr;33(2):220-9. doi: 10.1053/j.seminoncol.2005.12.012. Semin Oncol. 2006. PMID: 16616069 Review.
Cited by
-
GIFT4 fusokine converts leukemic B cells into immune helper cells.J Transl Med. 2016 Apr 27;14(1):106. doi: 10.1186/s12967-016-0865-1. J Transl Med. 2016. PMID: 27118475 Free PMC article.
-
Human CXCR5+ PD-1+ CD8 T cells in healthy individuals and patients with hematologic malignancies.Eur J Immunol. 2021 Mar;51(3):703-713. doi: 10.1002/eji.202048761. Epub 2020 Nov 23. Eur J Immunol. 2021. PMID: 33098668 Free PMC article.
-
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6250-5. doi: 10.1073/pnas.0901166106. Epub 2009 Mar 30. Proc Natl Acad Sci U S A. 2009. PMID: 19332800 Free PMC article.
-
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.Blood. 2013 Feb 28;121(9):1612-21. doi: 10.1182/blood-2012-09-457531. Epub 2012 Dec 17. Blood. 2013. PMID: 23247726 Free PMC article.
-
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.Blood. 2005 Nov 15;106(10):3515-23. doi: 10.1182/blood-2005-03-1214. Epub 2005 Aug 4. Blood. 2005. PMID: 16081691 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous